Clinical Trials
38 trialsNCT05304936 2026-04-15
HCW9218 for Advanced Pancreatic Cancer
ImmunityBio, Inc.
Phase 1/2 Completed
NCT02077881 2026-04-03
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Lumos Pharma
Phase 1/2 Completed
NCT05586516 2026-03-30
A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer
iOnctura
Phase 1/2 Completed
NCT02705196 2026-02-24
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Lokon Pharma AB
Phase 1/2 Completed
NCT03193190 2025-11-21
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT03184870 2025-10-09
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Completed
NCT04257448 2025-09-30
SEPION
GWT-TUD GmbH
Phase 1/2 Completed
NCT04247165 2025-03-12
LAPTOP
Herlev Hospital
Phase 1/2 Completed
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT03267316 2024-08-22
CANFOUR
Cantargia AB
Phase 1/2 Completed
NCT02024009 2024-07-25
SCALOP-2
University of Oxford
Phase 1/2 Completed
NCT04742959 2024-04-26
Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors
TransThera Sciences (Nanjing), Inc.
Phase 1/2 Completed
NCT03611556 2023-10-03
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
MedImmune LLC
Phase 1/2 Completed
NCT03840915 2023-08-21
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Phase 1/2 Completed
NCT03872791 2023-06-08
A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1/2 Completed
NCT02620865 2023-05-15
BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Barbara Ann Karmanos Cancer Institute
Phase 1/2 Completed
NCT02194829 2023-04-25
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02210559 2023-03-02
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Kyntra Bio
Phase 1/2 Completed
NCT01647828 2023-02-15
ALPINE
Mereo BioPharma
Phase 1/2 Completed
NCT04481009 2022-12-12
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Eucure (Beijing) Biopharma Co., Ltd
Phase 1/2 Completed
NCT02762981 2022-12-06
Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors
Corcept Therapeutics
Phase 1/2 Completed
NCT03085914 2022-09-23
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Incyte Corporation
Phase 1/2 Completed
NCT03086369 2022-06-28
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
Eli Lilly and Company
Phase 1/2 Completed
NCT02379247 2022-06-07
BYL719 and Nab-Paclitaxel in Locally Recurrent or Metastatic HER-2 Negative Breast Cancer
University of Kansas Medical Center
Phase 1/2 Completed
NCT02810418 2022-03-15
Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT01757288 2021-10-28
Phase I/II NabPaclitaxel, Paclitaxel&Carboplatin w RTX Followed by Consolidation in Patients w Favorable Prognosis Inoperable Stage IIIA/B NSCLC
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT02574078 2021-05-06
CheckMate370
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02733250 2021-02-16
URCOH-PMS-001
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 1/2 Completed
NCT00851877 2020-08-21
Nab-Paclitaxel, Cisplatin, and Cetuximab With Concurrent Radiation Therapy for Locally Advanced Head and Neck Cancer
University of Texas Southwestern Medical Center
Phase 1/2 Completed
NCT01962103 2019-12-27
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
Celgene
Phase 1/2 Completed
NCT01858883 2019-07-18
Safety Study of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
Incyte Corporation
Phase 1/2 Completed
NCT01893801 2019-05-29
Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA
Pancreatic Cancer Research Team
Phase 1/2 Completed
NCT01730222 2017-09-01
PACT-19
IRCCS San Raffaele
Phase 1/2 Completed
NCT00748553 2017-07-26
VA
University of Utah
Phase 1/2 Completed
NCT02273713 2017-05-31
ACTION
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1/2 Completed
NCT02109341 2017-02-03
NabucCO
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 1/2 Completed
NCT01488552 2016-08-18
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
Pancreatic Cancer Research Team
Phase 1/2 Completed
NCT02382263 2016-07-06
FRAGANCE
PH Research, S.L.
Phase 1/2 Completed